Selecta biosciences, inc (SELB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Grant and collaboration revenue

0

6,654

0

13

10

903

0

0

0

-

27

26

-

-

-

-

-

-

-

Grant and collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

137

-

1,048

2,017

2,088

1,607

1,236

Operating expenses:
Research and development

14,724

15,152

8,104

12,134

7,353

10,256

11,885

14,407

11,139

13,623

9,504

10,994

11,044

11,033

6,021

6,000

6,648

5,483

5,314

General and administrative

4,098

4,072

3,690

4,114

4,513

5,146

4,056

4,362

4,674

5,671

4,377

4,903

3,875

5,757

2,495

2,418

2,381

2,195

2,238

Total operating expenses

18,822

19,224

11,794

16,248

11,866

15,402

15,941

18,769

15,813

19,294

13,881

15,897

14,919

16,790

8,516

8,418

9,029

7,678

7,552

Loss from operations

-18,822

-12,570

-11,794

-16,235

-11,856

-14,499

-15,941

-18,769

-15,813

-19,277

-13,854

-15,871

-14,782

-13,860

-7,468

-6,401

-6,941

-6,071

-6,316

Investment income

240

127

184

246

277

221

295

246

288

238

165

101

113

113

98

10

13

25

62

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-673

-

-

-

0

-

-

-

-

Foreign currency transaction (loss), net

82

-14

7

-10

-30

23

26

84

-13

-10

-30

82

-165

-96

-51

-158

-220

668

-246

Interest expense

273

335

388

400

396

395

384

365

350

359

268

279

300

322

311

310

310

334

330

Change in fair value of warrant liabilities

846

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other (expense), net

-1

-1,239

-3

5

-69

-1

3

8

0

-

-16

0

-

82

4

-64

-18

-13

-

Net loss

-19,620

-14,888

-11,994

-16,394

-12,074

-14,651

-16,001

-18,796

-15,888

-19,544

-14,676

-15,967

-15,134

-14,083

-7,728

-6,923

-7,476

-5,725

-6,867

Stock‑based compensation expense

1,409

-

-

-

1,180

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Temporary Equity, Accretion to Redemption Value, Adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,210

2,356

-

-

Accretion of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,836

1,562

Net Income (Loss) Available to Common Stockholders, Basic

-

-

-11,994

-16,394

-

-

-16,001

-18,796

-15,888

-

-

-

-15,134

-14,083

-7,728

-9,133

-9,832

-7,561

-8,429

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

37

Net loss

-19,620

-14,888

-11,994

-16,394

-12,074

-14,651

-16,001

-18,796

-15,888

-19,544

-14,676

-15,967

-15,134

-14,083

-7,728

-6,923

-7,476

-5,725

-6,867

Other comprehensive loss:
Foreign currency translation adjustment

-60

10

-5

7

22

-40

-42

-90

19

-1

-1

-43

123

88

15

170

231

-800

245

Unrealized gain on securities

0

0

-3

1

2

0

1

12

3

-10

5

10

15

-52

16

0

0

0

-

Total comprehensive loss

-19,680

-14,878

-12,002

-16,386

-12,050

-14,691

-16,042

-18,874

-15,866

-19,555

-14,672

-16,000

-14,996

-14,047

-7,697

-6,753

-7,245

-6,525

-6,622

Net loss per share:
Net loss per share attributable to common stockholders—basic and diluted (in dollars per share)

-0.21

-0.28

-0.26

-0.37

-0.31

-0.66

-0.71

-0.84

-0.71

-0.87

-0.66

-0.85

-0.82

3.81

-0.43

-2.75

-4.52

-3.50

-3.93

Weighted average common shares outstanding:
Basic and diluted (in shares)

94,723

52,483

46,407

44,855

38,447

22,452

22,403

22,355

22,345

22,329

22,082

18,814

18,474

18,370

18,108

3,322

2,175

2,159

2,147